Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2024-11-20 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates by shareholders. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and informs about the loss and the process to issue a Letter of Confirmation. The content is a regulatory announcement related to share certificate loss, not a financial report, meeting material, or management information. It does not contain financial data or results, nor is it a report publication announcement. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-11-20 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges (BSE and NSE) regarding the launch of a pharmaceutical product (Breztri Aerosphere) by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval (Import and Market Permission) but does not contain any financial data, report, or detailed financial performance. The document is an announcement of a product launch and a regulatory update, not a financial report or detailed filing. The length is only 1543 characters, indicating it is a brief announcement rather than a full report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is also not related to management changes, voting results, or capital changes. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance-related communications that do not fit other categories.
2024-11-18 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) announcing the launch of a pharmaceutical product (Breztri Aerosphere) by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval (Form CT-20) but does not contain any financial data, earnings information, or detailed report content. The document is short (1543 characters) and serves as an announcement to be taken on record rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial disclosures. It is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement to the stock exchanges that does not fit other specific categories.
2024-11-18 English
Please find the enclosed copy of the newspaper publication of the financial results for the quarter and half year ended September 30, 2024.
Regulatory Filings
2024-11-18 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains financial data for a quarter ended 30/09/2024 and comparative figures for the previous quarter and year ended 31/03/2024. It includes unaudited quarterly figures and audited annual figures, with key financial metrics such as total income, net profit before and after tax, comprehensive income, equity share capital, and earnings per share. The presence of quarterly financial data and the unaudited status indicates this is a quarterly or interim financial report rather than a full annual report or earnings release summary. The document length is short but contains substantive financial data, so it is not merely an announcement or certification. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q2 2025
2024-11-18 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing the unaudited financial results for the quarter and half year ended September 30, 2024. It contains summarized financial performance data for Q2 2024 and H1 2024, including revenue and profit figures. The document also includes commentary from the CFO and Managing Director, key milestones, product launch information, and board changes. The presence of actual financial data and analysis for a quarterly period indicates this is a comprehensive interim/quarterly financial report rather than just an earnings release or announcement. The document length (6342 characters) supports it being a substantive report rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2024
2024-11-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.